which has yet to be defined by structural biology techniques. We have probed these isoform differences with a ligand series derived from the potent SK1-selective inhibitor, PF-543. Here we show how it is possible, even with relatively conservative changes in compound structure, to systematically tune the activity profile of a ligand from ca. 100-fold SK1-selective inhibition, through equipotent SK1/SK2
鞘氨醇激酶(SK1和SK2)催化
鞘氨醇向1-
磷酸鞘氨醇的转化,并在脂质信号传导和细胞反应中起关键作用。SK2的同工型
氨基酸序列差异到最近可用的SK1晶体结构上的映射表明,SK2中与脂质结合的“ J通道”的底部存在细微的结构差异,其结构尚待确定
生物学技术。我们已经用衍生自强效SK1选择性
抑制剂PF-543的
配体系列探索了这些同工型差异。在这里,我们显示了即使化合物结构发生相对保守的变化,也有可能系统地调节ca的
配体活性。通过等效的SK1 / SK2抑制,可实现100倍的SK1选择性抑制,